A Case of Ticagrelor Resistance

  • Jahanzeb Malik Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi, Punjab, Pakistan


Ticagrelor, coronary artery disease, stent thrombosis, dual anti-platelet therapy


Ticagrelor is a directly acting cyclopentyltriazolo-pyrimidine which does not require conversion into an active metabolite. It inhibits the P2Y12 receptors on platelets reversibly. Unlike clopidogrel and prasugrel, resistance to ticagrelor is rarely reported. Various mechanisms have been proposed for this resistance. The case of a 62-year-old man with diabetes who had undergone index percutaneous coronary intervention (PCI) 22 days previously is described. The patient presented to us with stent thrombosis. His primary PCI was successfully carried out with a drug-eluting stent. He showed resistance to ticagrelor on thromboelastography platelet mapping. He responded well to prasugrel (another P2Y12 inhibitor) in combination with aspirin.



  • Lee OH, Kim BK, Hong SJ, Kim S, Ahn CM, Shin DH, et al. Determinants and clinical outcomes of extended dual antiplatelet therapy over 3 years after drug-eluting stent implantation: a retrospective analysis. Yonsei Med J 2020;61(7):597–605. doi: 10.3349/ymj.2020.61.7.597. PMID: 32608203; PMCID: PMC7329747.
  • Sucato V, Corrado E, Castellana C, Carella M, Raso S, Coppola G, et al. Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention. J Cardiovasc Med (Hagerstown) 2017;18(6):450–451. doi: 10.2459/JCM.0000000000000516. PMID: 28306694.
  • Liu Z, Tian R, Wang Y, Chen Q, Li J, Xu L, et al. Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes. Thromb Haemost 2020;120(8):1221–1229. doi: 10.1055/s-0040-1713375. PMID: 32668483.
  • Kubica J, Adamski P, Ostrowska M, Kozi?ski M, Obo?ska K, Laskowska E, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials 2015;16:198. doi: 10.1186/s13063-015-0724-z. PMID: 25925591; PMCID: PMC4424595.
  • Pollack CV Jr, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, et al; PLATO Investigators. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clin Cardiol 2017;40(6):390–398. doi: 10.1002/clc.22733. PMID: 28598510; PMCID: PMC6490557.
  • Cheng D, Zhao S, Hao Y. Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients.Biosci Rep<7em> 2020;40(7):BSR20201346. doi: 10.1042/BSR20201346. PMID: 32639536; PMCID: PMC7364512.
  • Published: 2021-07-13

    Issue: 2021: Vol 8 No 7 (view)

    Section: Articles

    How to cite:
    Malik J. A Case of Ticagrelor Resistance. EJCRIM 2021;8 doi:10.12890/2021_002719.

    Similar Articles

    You may also start an advanced similarity search for this article.